Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients

28 Sept 2024

Abstract excerpt

Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We phenotypically and functionally analyzed blood samples from 46 patients focusing on CD16+ NK cells, CD16+ T cells and CD16+...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39342291
DOI: 10.1186/s12943-024-02123-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patientsPMID 39342291Read ↗

CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer AnalysisSemantic proximity Read ↗

Nonclassical monocytes are prone to migrate into tumor in diffuse large B-cell lymphomaSemantic proximity Read ↗

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcomeSemantic proximity Read ↗

Increased frequency of CD4+ cells expressing CD161 in cancer patients.Semantic proximity Read ↗

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>.Semantic proximity Read ↗

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer CellsSemantic proximity Read ↗

Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.Semantic proximity Read ↗

Determination of HLA-DR level in cytotoxic T lymphocytes: a new validated tool to predict breast cancer response to treatmentSemantic proximity Read ↗

SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subsetSemantic proximity Read ↗

CD16a<sup>high</sup> NK cell infiltration and spatial relationships with T cells and macrophages can predict improved progression-free survival in high grade ovarian cancerSemantic proximity Read ↗

High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.